Zometa, Reclast and Boniva infusions have been linked to a rare inflammatory eye disease, according to a letter published in the “New England Journal of Medicine” (NEJM). The Australian doctors who authored the letter wrote that infusions of these drugs should be “used with caution, or avoided altogether, in patients with acute ocular inflammation or a history of inflammatory eye disease or uveitis.”
Zometa, Reclast and Boniva are part of a class of drugs known as bisphosphonates, which also includes Fosamax, Didronel, Boniva, Aredia, Actonel, and Skelid. They were first approved by the Food & Drug Administration (FDA) to reduce the risk of bone fracture and to increase bone mass in people with osteoporosis. Bisphosphonates are also administered via infusion to slow bone turnover in people who have cancer that has spread to their bones, and to lower excessive levels of calcium in the blood in some people with cancer. Bisphosphonates are also used to treat Paget’s disease of bone. (more…)

